ARCHIVES

DCCP Board Gives Concept Approval To RFA For Biochemical Epidemiolgy, New And Recompeting Contract Program

This article is from The Cancer Letter archive.

Vol. 09 No. 36 | September 23, 1983

Download PDF Visit The Full Archive

Related Articles

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

August 30, 2013

QOL Of Young Survivors Equal To Other Children

February 25, 2005

Congress Approves FY 1980 HEW Funds

November 23, 1979

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

NCI Letter to HCFA Outlines Positions, Offers Glimpse of Tactics

September 27, 1996

SWOG Launching New Study Based on Recurrence Test Scores

April 29, 2011